Zu den Effekten von Gesundheitsreform- und Gesundheitsstrukturgesetz auf den Arzneimittelmarkt: auf dem Weg von der korporativen zur staatlichen Regulierung?

Manfred Erbsland and Eberhard Wille

No 94-11, ZEW Discussion Papers from ZEW - Leibniz Centre for European Economic Research

Abstract: From the viewpoint of regulation, this paper investigates the effects of both the Health Care Refonn Act (Gesundheitsreformgesetz, GRG) and the Structural Health Care Act (Gesundheitsstrukturgesetz, GSG) on phannaceutical markets. Apart from the change in the intensity of regulation, the main focus is on the relative significance of self-regulation (or corporatism) on the one hand, and govemment regulation on the other. As our analysis demonstrates, in contrast to GRG, the impact of GSG has been - at least temporarily - to shift emphasis away from corporatism towards regulation directly imposed by govemment.

Date: 1994
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.econstor.eu/bitstream/10419/29481/1/043546129.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:zbw:zewdip:9411

Access Statistics for this paper

More papers in ZEW Discussion Papers from ZEW - Leibniz Centre for European Economic Research Contact information at EDIRC.
Bibliographic data for series maintained by ZBW - Leibniz Information Centre for Economics ().